Generic Name and Formulations:
Etomidate 2mg/mL; soln for IV inj.
Indications for AMIDATE:
For the induction of general anesthesia. For the supplementation of subpotent anesthetic agents (eg, nitrous oxide in oxygen) during maintenance of anesthesia for short operative procedures (eg, dilation and curettage, cervical conization).
Adults and Children:
<10yrs: not recommended. Induction: Give by IV inj over 30–60 seconds. ≥10yrs: Individualize. Usual range: 0.2–0.6mg/kg. Usual dose: 0.3mg/kg. Elderly: may need to reduce dose. Supplementation: smaller increments may be given.
To be administered only by those experienced in general anesthesia. May reduce plasma cortisol and aldosterone concentrations; consider exogenous replacement in patients undergoing severe stress. Pediatric neurotoxicity risk with repeated or prolonged use. Renal impairment. Elderly (may induce cardiac depression). Labor & delivery: not recommended. Pregnancy (Cat.C). Nursing mothers.
Concomitant IV fentanyl and other neuroactive drugs; may need to adjust etomidate dose.
Transient venous pain on inj, transient skeletal muscle movements including myoclonus, hyper- or hypoventilation, apnea, laryngospasm, hiccup, snoring, hyper- or hypotension, tachycardia, arrhythmias, post-op nausea/vomiting.
Vial—10mL, 20mL; Ampul—10mL, 20mL; Abboject syringe—20mL
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|